Q-omics provides the consensus-scored FBXO30 profile across patient tissues and cancer cell-line models. FBXO30 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FBXO30 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FBXO30 RNA expression shows 20,947 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, THCA, and THYM as cancer lineages where FBXO30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO30 survival associations across molecular data types. FBXO30 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO30 RNA expression–survival associations across cancer types. High FBXO30 expression shows unfavorable associations in LIHC, OV and MESO, but favorable associations in KIRC, THYM and GBM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FBXO30 RNA expression.
This table summarizes FBXO30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXO30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO30 shows lower tumor expression in THCA, BLCA and KIRC and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher FBXO30 RNA expression in normal versus tumor tissue (log2 FC = −1.522, t-test p < 0.001).
This table shows molecular features associated with FBXO30 in patient tissues and cancer cell lines. In patient samples, FBXO30 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
